Orient Europharma Co Ltd (4120.TWO) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · Taiwan · ISIN TW0004120001

Price
43.50 TWD
Market cap
3.77 bn TWD
P/E (2025)
–
P/S (2025)
0.82
Dividend yield
0.00 %
Net margin
-12.35 %
Return on equity (ROE)
-7.72 %
Return on assets (ROA)
-4.65 %

Orient Europharma Co Ltd financials

Fiscal year20242025
Revenue4.39 bn TWD4.60 bn TWD
Gross profit2.07 bn TWD2.24 bn TWD
Operating income13.33 m TWD-298.82 m TWD
EBIT-22.76 m TWD-198.97 m TWD
Net income-283.93 m TWD-567.39 m TWD

Full history since 2008, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Orient Europharma Co Ltd

Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include weight management, andrology, cardiovascular, respiratory, neurology, cardiovascular, metabolism, obstetrics and gynecology, antibiotic, immunology, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk under the Karihome brand name; and healthcare supplements for liquid nutrition, regular blood lipids, L-arginines, agile movements, and improved sleep qualities under the Nutrifuel brand name. In addition, the company offers dermo and cosmetic products under the Cumlaude Labs, AGLabs, Bio-Oil, and ISISPHARMAs brand names. Further, it engages in the research and development of Multikine, an immunotherapy drug for head and neck cancer, which is in Phase III clinical study; and 2ccPA, a derivative of phospholipid to patients with symptomatic osteoarthritis of the knee, which is in Phase I clinical trial. Orient EuroPharma Co., Ltd. was incorporated in 1982 and is based in Taipei, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.